title: Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension.
abstract: In a randomized, double-masked, parallel study, one drop of 0.003% (1 microgram; n = 9) or 0.01% (3 micrograms; n = 10) PhXA34, a new phenyl-substituted prostaglandin F2 alpha analogue (13,14-dihydro-15[R,S]-17-phenyl-18,19,20-trinor-prostaglandin F2 alpha-1-isopropyl ester), or its vehicle (n = 10) was applied topically twice daily for 6 days to one eye in each of 29 patients with ocular hypertension. Compared with either baseline, contralateral, or vehicle control values, PhXA34 caused a significant (P < .001) dose-dependent reduction of intraocular pressure. The reduction lasted at least 12 hours after each drop and 24 to 48 hours after the last drop, with a significant (P < .0001) mean +/- SEM reduction of as much as 10 +/- 1 mm Hg (40%). Conjunctival hyperemia was not produced by 0.003% PhXA34, but was noted in some eyes treated with 0.01% PhXA34, and after repeated tonometry with either concentration. The prostaglandin analogue did not produce clinically obvious miosis, anterior chamber flare or cellular response, or any subjective adverse effects. PhXA34 is a potent, effective, and well-tolerated ocular hypotensive agent based on our results in this small, short-term study. Its potential as a new drug for glaucoma therapy warrants further investigation in long-term, larger studies.
authors.affiliation: Department of Ophthalmology, Mt Sinai School of Medicine, New York, NY.
authors.forename: C B
authors.initials: CB
authors.lastname: Camras
authors.forename: R A
authors.initials: RA
authors.lastname: Schumer
authors.forename: A
authors.initials: A
authors.lastname: Marsk
authors.forename: J S
authors.initials: JS
authors.lastname: Lustgarten
authors.forename: J B
authors.initials: JB
authors.lastname: Serle
authors.forename: J
authors.initials: J
authors.lastname: Stjernschantz
authors.forename: L Z
authors.initials: LZ
authors.lastname: Bito
authors.forename: S M
authors.initials: SM
authors.lastname: Podos
mesh_terms: D000328:Adult; D000368:Aged; D003228:Conjunctiva / Q000098:blood supply; D004311:Double-Blind Method; D006801:Humans; D006940:Hyperemia / Q000139:chemically induced; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D009994:Osmolar Concentration; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost